The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...
MedPage Today on MSN
Drug Holidays for Advanced Kidney Cancer a Consideration for Selected Patients
DENVER -- Planned treatment "holidays" can help lessen the toxicity burden of tyrosine kinase inhibitors (TKIs) for selected ...
TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...
ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma ...
MedPage Today on MSN
Better Survival in Kidney Cancer After Stopping Therapy for Immune-Related AEs
D ENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) ...
Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. | Genmab has shed another ...
Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...
During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...
Immunotherapy, which harnesses our body's own immune system to fight cancer, has revolutionized modern oncology. Yet despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback